- Multiple hereditary exostosis (MHE), a rare genetic disorder characterized by benign bone tumors, is gaining increasing clinical attention in the Asia-Pacific region due to rising awareness, improved diagnostic capabilities, and growing access to specialized orthopedic and genetic services in urban centers
- The escalating demand for early diagnosis and advanced therapeutic interventions is primarily fueled by improved healthcare infrastructure, government support for rare disease management, and the expansion of genetic screening programs in countries such as China, Japan, and India
- China dominated the Asia-Pacific multiple hereditary exostosis market with the largest revenue share of 39.9% in 2024, supported by a growing pediatric patient population, advancements in genomic medicine, and the presence of regional centers of excellence focusing on skeletal dysplasias
- India is expected to be the fastest-growing country in the Asia-Pacific multiple hereditary exostosis market during the forecast period, driven by enhanced rare disease policies, expanding clinical trial activity, and the growing role of patient advocacy organizations
- Sessile segment dominated the Asia-Pacific multiple hereditary exostosis market with a market share of 59.1% in 2024, driven by its higher prevalence near joints and increased such likelihood of causing nerve compression, prompting earlier clinical detection and intervention
